A systematic literature review of real-world treatment outcomes of small cell lung cancer
Robust evidence from real-world studies is needed to aid decision-makers and other stakeholders in choosing the best treatment options for patients. The objective of this work was to assess real-world outcomes of treatment strategies for limited- and extensive-stage small cell lung cancer (SCLC) pri...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2022-07, Vol.101 (26), p.e29783-e29783 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e29783 |
|---|---|
| container_issue | 26 |
| container_start_page | e29783 |
| container_title | Medicine (Baltimore) |
| container_volume | 101 |
| creator | Stokes, Michael Berfeld, Noami Gayle, Alicia Descoteaux, Andrew Rohrmoser, Oscar Franks, April |
| description | Robust evidence from real-world studies is needed to aid decision-makers and other stakeholders in choosing the best treatment options for patients. The objective of this work was to assess real-world outcomes of treatment strategies for limited- and extensive-stage small cell lung cancer (SCLC) prior to the global introduction of immunotherapies for this disease.
Searches were conducted in MEDLINE and Embase to identify articles published in English from October 1, 2015, through May 20, 2020. Searches were designed using a combination of Medical Subject Heading (Medline), Emtree (Embase subject headings), and free-text terms such as SCLC. Observational studies reporting data on outcomes of initial treatment strategies in patients with limited- and extensive-stage SCLC were included. Studies with limited sample sizes ( |
| doi_str_mv | 10.1097/MD.0000000000029783 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9239604</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2684100384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4501-94bd264de72ad82e1a0b71e65259f2ee328fb84671eeb039e15c4942a1dd822a3</originalsourceid><addsrcrecordid>eNpdkcFu1DAQhi0EoqXwBEgoRy4p47ETxxekqgVaqRUXOHCyHGfSDThxsZ2u-vZ42VIKPtij8Tf_jP0z9prDMQet3l2dHcPfhVp14gk75I1o60a38umj-IC9SOk7ABcK5XN2IBqlFKA8ZN9OqnSXMs02T67yU6Zo8xqpinQ70bYKY4msr7ch-qHKJc4zLbkKa3ZhprQD0my9rxyVza_LdeXs4ii-ZM9G6xO9uj-P2NePH76cnteXnz9dnJ5c1k42wGst-wFbOZBCO3RI3EKvOLUNNnpEIoHd2HeyLTnqQWjijZNaouVDwdGKI_Z-r3uz9jMNrkwXrTc3cZptvDPBTubfm2XamOtwazQK3YIsAm_vBWL4uVLKZp7S7jV2obAmg20nOYDodqjYoy6GlCKND204mJ0p5urM_G9KqXrzeMKHmj8uFEDugW3wxYD0w69bimZTPj5vfus1SmONgAgKONQlI7n4BaB8mLY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2684100384</pqid></control><display><type>article</type><title>A systematic literature review of real-world treatment outcomes of small cell lung cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Stokes, Michael ; Berfeld, Noami ; Gayle, Alicia ; Descoteaux, Andrew ; Rohrmoser, Oscar ; Franks, April</creator><creatorcontrib>Stokes, Michael ; Berfeld, Noami ; Gayle, Alicia ; Descoteaux, Andrew ; Rohrmoser, Oscar ; Franks, April</creatorcontrib><description>Robust evidence from real-world studies is needed to aid decision-makers and other stakeholders in choosing the best treatment options for patients. The objective of this work was to assess real-world outcomes of treatment strategies for limited- and extensive-stage small cell lung cancer (SCLC) prior to the global introduction of immunotherapies for this disease.
Searches were conducted in MEDLINE and Embase to identify articles published in English from October 1, 2015, through May 20, 2020. Searches were designed using a combination of Medical Subject Heading (Medline), Emtree (Embase subject headings), and free-text terms such as SCLC. Observational studies reporting data on outcomes of initial treatment strategies in patients with limited- and extensive-stage SCLC were included. Studies with limited sample sizes (<100 patients), enrolled all patients prior to 2010, or did not report outcomes for limited- and extensive-stage SCLC separately were excluded. Data were extracted into a predesigned template by a single researcher. All extractions were validated by a second researcher, with disagreements resolved via consensus.
Forty articles were included in this review. Most enrolled patients from the United States (n = 18 articles) or China (n = 12 articles). Most examined limited-stage (n = 27 articles) SCLC. All studies examined overall survival as the primary outcome. Articles investigating limited-stage SCLC reported outcomes for surgery, chemotherapy and/or radiotherapy, and adjuvant prophylactic cranial irradiation. In studies examining multiple treatment strategies, chemoradiotherapy was the most commonly utilized therapy (56%-82%), with chemotherapy used in 18% to 44% of patients. Across studies, median overall survival was generally higher for chemoradiotherapy (15-45 months) compared with chemotherapy alone (6.0-15.6 months). Studies of extensive-stage SCLC primarily reported on chemotherapy alone, consolidative thoracic radiotherapy, and radiotherapy for patients presenting with brain metastases. Overall survival was generally lower for patients receiving chemotherapy alone (median: 6.4-16.5 months; 3 years, 5%-14.9%) compared with chemotherapy in combination with consolidative thoracic radiotherapy (median: 12.1-18.0 months; 3 years, 15.0%-18.1%). Studies examining whole-brain radiotherapy for brain metastases reported lower median overall survival (5.6-8.7 months) compared with stereotactic radiosurgery (10.0-14.5 months).
Under current standard of care, which has remained relatively unchanged over the past few decades, prognosis remains poor for patients with SCLC.</description><identifier>ISSN: 1536-5964</identifier><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000029783</identifier><identifier>PMID: 35777024</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Brain Neoplasms - secondary ; Cranial Irradiation ; Humans ; Lung Neoplasms - pathology ; Small Cell Lung Carcinoma - pathology ; Systematic Review and Meta-Analysis ; Treatment Outcome</subject><ispartof>Medicine (Baltimore), 2022-07, Vol.101 (26), p.e29783-e29783</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4501-94bd264de72ad82e1a0b71e65259f2ee328fb84671eeb039e15c4942a1dd822a3</citedby><cites>FETCH-LOGICAL-c4501-94bd264de72ad82e1a0b71e65259f2ee328fb84671eeb039e15c4942a1dd822a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239604/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239604/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35777024$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stokes, Michael</creatorcontrib><creatorcontrib>Berfeld, Noami</creatorcontrib><creatorcontrib>Gayle, Alicia</creatorcontrib><creatorcontrib>Descoteaux, Andrew</creatorcontrib><creatorcontrib>Rohrmoser, Oscar</creatorcontrib><creatorcontrib>Franks, April</creatorcontrib><title>A systematic literature review of real-world treatment outcomes of small cell lung cancer</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Robust evidence from real-world studies is needed to aid decision-makers and other stakeholders in choosing the best treatment options for patients. The objective of this work was to assess real-world outcomes of treatment strategies for limited- and extensive-stage small cell lung cancer (SCLC) prior to the global introduction of immunotherapies for this disease.
Searches were conducted in MEDLINE and Embase to identify articles published in English from October 1, 2015, through May 20, 2020. Searches were designed using a combination of Medical Subject Heading (Medline), Emtree (Embase subject headings), and free-text terms such as SCLC. Observational studies reporting data on outcomes of initial treatment strategies in patients with limited- and extensive-stage SCLC were included. Studies with limited sample sizes (<100 patients), enrolled all patients prior to 2010, or did not report outcomes for limited- and extensive-stage SCLC separately were excluded. Data were extracted into a predesigned template by a single researcher. All extractions were validated by a second researcher, with disagreements resolved via consensus.
Forty articles were included in this review. Most enrolled patients from the United States (n = 18 articles) or China (n = 12 articles). Most examined limited-stage (n = 27 articles) SCLC. All studies examined overall survival as the primary outcome. Articles investigating limited-stage SCLC reported outcomes for surgery, chemotherapy and/or radiotherapy, and adjuvant prophylactic cranial irradiation. In studies examining multiple treatment strategies, chemoradiotherapy was the most commonly utilized therapy (56%-82%), with chemotherapy used in 18% to 44% of patients. Across studies, median overall survival was generally higher for chemoradiotherapy (15-45 months) compared with chemotherapy alone (6.0-15.6 months). Studies of extensive-stage SCLC primarily reported on chemotherapy alone, consolidative thoracic radiotherapy, and radiotherapy for patients presenting with brain metastases. Overall survival was generally lower for patients receiving chemotherapy alone (median: 6.4-16.5 months; 3 years, 5%-14.9%) compared with chemotherapy in combination with consolidative thoracic radiotherapy (median: 12.1-18.0 months; 3 years, 15.0%-18.1%). Studies examining whole-brain radiotherapy for brain metastases reported lower median overall survival (5.6-8.7 months) compared with stereotactic radiosurgery (10.0-14.5 months).
Under current standard of care, which has remained relatively unchanged over the past few decades, prognosis remains poor for patients with SCLC.</description><subject>Brain Neoplasms - secondary</subject><subject>Cranial Irradiation</subject><subject>Humans</subject><subject>Lung Neoplasms - pathology</subject><subject>Small Cell Lung Carcinoma - pathology</subject><subject>Systematic Review and Meta-Analysis</subject><subject>Treatment Outcome</subject><issn>1536-5964</issn><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkcFu1DAQhi0EoqXwBEgoRy4p47ETxxekqgVaqRUXOHCyHGfSDThxsZ2u-vZ42VIKPtij8Tf_jP0z9prDMQet3l2dHcPfhVp14gk75I1o60a38umj-IC9SOk7ABcK5XN2IBqlFKA8ZN9OqnSXMs02T67yU6Zo8xqpinQ70bYKY4msr7ch-qHKJc4zLbkKa3ZhprQD0my9rxyVza_LdeXs4ii-ZM9G6xO9uj-P2NePH76cnteXnz9dnJ5c1k42wGst-wFbOZBCO3RI3EKvOLUNNnpEIoHd2HeyLTnqQWjijZNaouVDwdGKI_Z-r3uz9jMNrkwXrTc3cZptvDPBTubfm2XamOtwazQK3YIsAm_vBWL4uVLKZp7S7jV2obAmg20nOYDodqjYoy6GlCKND204mJ0p5urM_G9KqXrzeMKHmj8uFEDugW3wxYD0w69bimZTPj5vfus1SmONgAgKONQlI7n4BaB8mLY</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Stokes, Michael</creator><creator>Berfeld, Noami</creator><creator>Gayle, Alicia</creator><creator>Descoteaux, Andrew</creator><creator>Rohrmoser, Oscar</creator><creator>Franks, April</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220701</creationdate><title>A systematic literature review of real-world treatment outcomes of small cell lung cancer</title><author>Stokes, Michael ; Berfeld, Noami ; Gayle, Alicia ; Descoteaux, Andrew ; Rohrmoser, Oscar ; Franks, April</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4501-94bd264de72ad82e1a0b71e65259f2ee328fb84671eeb039e15c4942a1dd822a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Brain Neoplasms - secondary</topic><topic>Cranial Irradiation</topic><topic>Humans</topic><topic>Lung Neoplasms - pathology</topic><topic>Small Cell Lung Carcinoma - pathology</topic><topic>Systematic Review and Meta-Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stokes, Michael</creatorcontrib><creatorcontrib>Berfeld, Noami</creatorcontrib><creatorcontrib>Gayle, Alicia</creatorcontrib><creatorcontrib>Descoteaux, Andrew</creatorcontrib><creatorcontrib>Rohrmoser, Oscar</creatorcontrib><creatorcontrib>Franks, April</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stokes, Michael</au><au>Berfeld, Noami</au><au>Gayle, Alicia</au><au>Descoteaux, Andrew</au><au>Rohrmoser, Oscar</au><au>Franks, April</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A systematic literature review of real-world treatment outcomes of small cell lung cancer</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>101</volume><issue>26</issue><spage>e29783</spage><epage>e29783</epage><pages>e29783-e29783</pages><issn>1536-5964</issn><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Robust evidence from real-world studies is needed to aid decision-makers and other stakeholders in choosing the best treatment options for patients. The objective of this work was to assess real-world outcomes of treatment strategies for limited- and extensive-stage small cell lung cancer (SCLC) prior to the global introduction of immunotherapies for this disease.
Searches were conducted in MEDLINE and Embase to identify articles published in English from October 1, 2015, through May 20, 2020. Searches were designed using a combination of Medical Subject Heading (Medline), Emtree (Embase subject headings), and free-text terms such as SCLC. Observational studies reporting data on outcomes of initial treatment strategies in patients with limited- and extensive-stage SCLC were included. Studies with limited sample sizes (<100 patients), enrolled all patients prior to 2010, or did not report outcomes for limited- and extensive-stage SCLC separately were excluded. Data were extracted into a predesigned template by a single researcher. All extractions were validated by a second researcher, with disagreements resolved via consensus.
Forty articles were included in this review. Most enrolled patients from the United States (n = 18 articles) or China (n = 12 articles). Most examined limited-stage (n = 27 articles) SCLC. All studies examined overall survival as the primary outcome. Articles investigating limited-stage SCLC reported outcomes for surgery, chemotherapy and/or radiotherapy, and adjuvant prophylactic cranial irradiation. In studies examining multiple treatment strategies, chemoradiotherapy was the most commonly utilized therapy (56%-82%), with chemotherapy used in 18% to 44% of patients. Across studies, median overall survival was generally higher for chemoradiotherapy (15-45 months) compared with chemotherapy alone (6.0-15.6 months). Studies of extensive-stage SCLC primarily reported on chemotherapy alone, consolidative thoracic radiotherapy, and radiotherapy for patients presenting with brain metastases. Overall survival was generally lower for patients receiving chemotherapy alone (median: 6.4-16.5 months; 3 years, 5%-14.9%) compared with chemotherapy in combination with consolidative thoracic radiotherapy (median: 12.1-18.0 months; 3 years, 15.0%-18.1%). Studies examining whole-brain radiotherapy for brain metastases reported lower median overall survival (5.6-8.7 months) compared with stereotactic radiosurgery (10.0-14.5 months).
Under current standard of care, which has remained relatively unchanged over the past few decades, prognosis remains poor for patients with SCLC.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>35777024</pmid><doi>10.1097/MD.0000000000029783</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1536-5964 |
| ispartof | Medicine (Baltimore), 2022-07, Vol.101 (26), p.e29783-e29783 |
| issn | 1536-5964 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9239604 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Brain Neoplasms - secondary Cranial Irradiation Humans Lung Neoplasms - pathology Small Cell Lung Carcinoma - pathology Systematic Review and Meta-Analysis Treatment Outcome |
| title | A systematic literature review of real-world treatment outcomes of small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A55%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20systematic%20literature%20review%20of%20real-world%20treatment%20outcomes%20of%20small%20cell%20lung%20cancer&rft.jtitle=Medicine%20(Baltimore)&rft.au=Stokes,%20Michael&rft.date=2022-07-01&rft.volume=101&rft.issue=26&rft.spage=e29783&rft.epage=e29783&rft.pages=e29783-e29783&rft.issn=1536-5964&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000029783&rft_dat=%3Cproquest_pubme%3E2684100384%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2684100384&rft_id=info:pmid/35777024&rfr_iscdi=true |